Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Omeros Corp (NQ: OMER )

17.56 USD +0.07 (+0.40%)
Official Closing Price Updated: 4:50 PM EDT, Apr 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Omeros Corp

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month. The I-SPY COVID-19... 
From Business Wire News Releases
Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well... 
From Business Wire News Releases
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Monday, March 1, 2021, after... 
From Business Wire News Releases
Omeros Hires Nadia Dac as Chief Commercial Officer
Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros,... 
From Business Wire News Releases
Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic... 
From Business Wire News Releases
Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference
Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference this week.... 
From Business Wire News Releases
Thinking about buying stock in Pfizer, China Automotive Systems, Omeros Corp, Nio, or FuelCell Energy?
InvestorsObserver issues critical PriceWatch Alerts for PFE, CAAS, OMER, NIO, and FCEL. 
From PR Newswire
CMS Confirms Continued Separate Payment for Omeros’ FDA-Approved OMIDRIA® in Ambulatory Surgery Centers
Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surgery... 
From Business Wire News Releases
Global Acute Myeloid Leukemia Therapeutics Market Could Exceed $3.5 Billion By 2027
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Acute Myeloid Leukemia Therapeutics Market Could Exceed $3.5 Billion By 2027
Financialnewsmedia.com News Commentary 
From PR Newswire
Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA
Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for... 
From Business Wire News Releases
Omeros Corporation Reports Third Quarter 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well... 
From Business Wire News Releases
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9, 2020, after the market... 
From Business Wire News Releases
Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development
Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today... 
From Business Wire News Releases
Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an... 
From Business Wire News Releases
Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit
Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting... 
From Business Wire News Releases
Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA
Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy... 
From Business Wire News Releases
Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs
Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The two-year... 
From Business Wire News Releases
Omeros to Present at the Cantor Virtual Global Healthcare Conference
Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week. The... 
From Business Wire News Releases
Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients
Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. The panel session,... 
From Business Wire News Releases
Thinking about buying stock in Unum Therapeutics, Omeros Corp, Workhorse Group, Norwegian Cruise Line, or Delta Air Lines?
InvestorsObserver issues critical PriceWatch Alerts for UMRX, OMER, WKHS, NCLH, and DAL. 
From PR Newswire
Omeros’ Investigational New Drug Application for OMS906 Cleared by FDA
Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA). OMS906 is... 
From Business Wire News Releases
Omeros Announces Pricing of Public Offerings
Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock (the “Shares”) at a public offering... 
From Business Wire News Releases
Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has commenced concurrent underwritten public offerings of $125,000,000 of shares of its common stock (the “Shares”) and $200,000,000... 
From Business Wire News Releases
Omeros Corporation Reports Second Quarter 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well... 
From Business Wire News Releases
Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome
Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody targeting mannan-binding... 
From Business Wire News Releases
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy... 
From Business Wire News Releases
Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress
Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be... 
From Business Wire News Releases
Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will... 
From Business Wire News Releases
Omeros Corporation Reports First Quarter 2020 Financial Results
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback